A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : hu14.18-Interleukin-2 fusion protein
Phase: Phase 2
Ages Eligible For Study: